Abstracts tagged "Macrophage"

Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Lei Zhou¹, Robert Sikorski¹, Seema Rogers¹, Stefan Costin², Mariusz Korkosz³, Maria Jaraczewska-Baumann⁴, Péterfai Éva⁵, Bernadette Rojkovich⁶, Janos Bartalos⁷, Emma Masteller¹, Hong Xiang¹, Brian Wong¹ and Julie Hambleton¹, ¹Five Prime Therapeutics, Inc., South San Francisco, CA, ²PRA Heath Sciences, Berlin, Germany, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴MedPolonia Sp. z o.o, Poznan, Poland, ⁵Drug Research Center, Balatonfüred, Hungary, ⁶Hospitaller Brothers of St. John of God, Budapest, Hungary, ⁷PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
Abstract Number: 20 • 2015 ACR/ARHP Annual Meeting
Role of the Epigenetic Regulator EZH2 in Proinflammatory Macrophage Polarization and Signaling in Rheumatoid Arthritis
Michelle Trenkmann¹, Eimear Linehan², Mary Canavan³, Douglas J. Veale⁴ and Ursula Fearon¹, ¹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ²St. Vincent's University Hospital Dublin, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin, Ireland, ⁴St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland
Background/Purpose: In rheumatoid arthritis (RA), synovial tissue macrophages (MΦ) are inherently involved in disease pathogenesis by producing inflammatory mediators and matrix-destructive enzymes. Depending on their…
Abstract Number: 2814 • 2015 ACR/ARHP Annual Meeting
IL-10 May Mitigate Cardiovascular Risk in Psoriatic Arthritis Via an Anti-Atherosclerotic Effect on Cellular Cholesterol Transport
Lucas McCaffrey¹, Iryna Voloshyna², Michael J. Littlefield², Eduard Zhurov³, Steven E. Carsons⁴, Elise Belilos⁵, Kristina Belostocki⁶, Lois Bonetti⁷, Gary Rosenblum⁶ and Allison B. Reiss², ¹Medicine, Division of Rheumatology, Winthrop-University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Winthrop-University Hospital, Mineola, NY, ⁴Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ⁵Winthrop University Hospital, Mineola, NY, ⁶Rheumatology, Winthrop University Hospital, Mineola, NY, ⁷Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: The increased risk of major adverse cardiovascular events (MACE) in patients who suffer from systemic inflammatory conditions such as Rheumatoid Arthritis (RA), Systemic Lupus…
Abstract Number: 795 • 2015 ACR/ARHP Annual Meeting
High Mobility Group Box-1 (HMGB1) Affects Macrophage Polarization and Phagocytosis in Systemic Lupus Erythematosus Patients
Fleur Schaper¹, Gerda Horst¹, Karina de Leeuw¹, Hendrika Bootsma¹, Pieter C Limburg², Peter Heeringa³, Marc Bijl⁴ and Johanna Westra⁵, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
High mobility group box-1 (HMGB1) affects macrophage polarization and phagocytosis in systemic lupus erythematosus patients. F Schaper, G Horst, K de Leeuw, H Bootsma, PC…
Abstract Number: 3217 • 2015 ACR/ARHP Annual Meeting
Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus
Jessica Doerner¹, Samantha Chalmers² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Kidney and skin involvement are common in systemic lupus erythematosus (SLE). Nephritis is seen in up to 60% of patients, and contributes significantly to…
Abstract Number: 935 • 2015 ACR/ARHP Annual Meeting
Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1
Quan-Bo Zhang^1,2, Jing-Guo Zhou³, Cong-Cong Yin¹, Yu-Feng Qing⁴, Chang-Gui Li⁵, Li Zhou¹ and Qing-Sheng Mi⁶, ¹Immunology Program, Department of Dermatology, Henry Ford Health System, Detroit, MI, ²Geriatrics, Affliated hospital of North Sichuan Medical College, Nanchong, China, ³Department of Rheumatology and Immunology, Affliated hospital of North Sichuan Medical College, Nanchong, China, ⁴Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nanchong, China, ⁵Affiliated Hospital of Qingdao University, Qingdao, China, ⁶Immunology, Dermatology, Henry Ford Health System, Detroit, MI
Background/Purpose: MicroRNAs (miRNAs) have been shown to serve as important regulators for inflammatory and immune responses and are implicated in several immune disorders including gouty…
Abstract Number: 1160 • 2015 ACR/ARHP Annual Meeting
DNA Hydroxylmethylation Regulates Pro-Inflammatory Cytokine Expression in Macrophages
Fangfang Sun^1,2, Renate E. Gay¹, Beat A. Michel¹, Shuang Ye², Steffen Gay¹, Michel Neidhart¹ and Emmanuel Karouzakis¹, ¹University Hospital Zurich, Center of Experimental Rheumatology, Switzerland, Zurich, Switzerland, ²Department of Rheumatology, South Campus, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China
Background/Purpose: Activated macrophages are found in the inflamed and hyperplasic synovial RA tissues. Macrophages are the main producers of high levels of pro-inflammatory cytokines such…
Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting
IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma
Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting
Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis
Naotake Tsuboi¹, Nobuhide Endo¹, Seiichi Matsuo² and Shoichi Maruyama¹, ¹Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…
Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Iain B. McInnes¹, Gerd Burmester², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, David Close⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, Sara Sandbach¹², Patricia C. Ryan¹³, Dominic Sinibaldi¹⁴, Wendy White¹³, Nadine A. Defranoux¹⁵ and Michael Weinblatt¹⁶, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, ⁷Med Clinic I, University of Cologne, koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹³Translational Sciences, MedImmune, Gaithersburg, MD, ¹⁴R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, ¹⁵Crescendo Bioscience Inc., South San Francisco, CA, ¹⁶Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Julie Hambleton¹, Lei Zhou¹, Seema Rogers¹, Sjoerd van Marle², Thijs van Iersel², James Zanghi¹, Emma Masteller¹, Kevin Baker¹ and Brian Wong¹, ¹Five Prime Therapeutics, South San Francisco, CA, ²PRA Health Sciences, Groningen, Netherlands
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…
Abstract Number: 1209 • 2014 ACR/ARHP Annual Meeting
Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase
Hao Li^1,2, Qi Wu¹, PingAr Yang¹, Zheng Wang³, Jun Li¹, Bao Luo¹, Jeffrey C. Edberg¹, Hui-Chen Hsu¹, John D. Mountz^1,4 and Robert P. Kimberly on behalf of PROFILE investigators⁵, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, ⁴Birmingham VA Medical Center, Birmingham, AL, ⁵Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Ibrutinib, a Btk kinase activity inhibitor, is a novel inhibitor under development for autoimmune disease therapy. We have shown that Btk was significantly upregulated…
Abstract Number: 1197 • 2014 ACR/ARHP Annual Meeting
Febuxostat Inhibits Monosodium Urate Crystal-Induced IL-1beta Secretion and Cell Death Via ROS- and Intracellular ATP-Dependent Pathways
Johji Nomura¹, Nathalie Busso², Mizuho Tamura¹, Tsunefumi Kobayashi¹ and Alexander So³, ¹Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo, Japan, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose: In gout, monosodium urate (MSU) crystals trigger acute inflammation. MSU has been reported to activate NLRP3 inflammasome via ROS-dependent pathways, which result in IL-1beta…
Abstract Number: 1199 • 2014 ACR/ARHP Annual Meeting
Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Rik Schelbergen¹, Wouter de Munter², Martijn van den Bosch³, Floris Lafeber⁴, Annet Sloetjes³, Thomas Vogl⁵, Johannes Roth⁵, Peter M. van der Kraan⁶, Arjen B. Blom³, Wim B van den Berg³ and Peter L. van Lent³, ¹Radboud university medical center, Nijmegen, Netherlands, ²Experimental rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose The main pathological feature of osteoarthritis (OA) is degradation of the articular cartilage. Other important hallmarks include subclinical inflammation of the synovium and ectopic…
Abstract Number: 969 • 2014 ACR/ARHP Annual Meeting
Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation
Alexander Misharin¹, Carla M. Cuda², Luisa Morales-Nebreda³, Gokhan Mutlu¹, GR Scott Budinger³ and Harris R. Perlman⁴, ¹Northwestern University, Chicago, IL, ²Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Pulmonary fibrosis has emerged as the leading cause of death in patients with Systemic Sclerosis (SSc). Currently available therapies are only marginally effective in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].